OR9Q2 Antibody

What is OR9Q2 and why is it a target of interest in research?

OR9Q2 (Olfactory Receptor, Family 9, Subfamily Q, Member 2) is a member of the G-protein coupled receptor 1 family responsible for detecting odor molecules. It functions as an odorant receptor in the olfactory system, playing a crucial role in detecting and processing odors . Recent research has identified OR9Q2 as being selectively tuned to 4-methylphenol, a food-related odor-active volatile with a characteristic horse stable-like, fecal odor quality . This selective functionality makes it particularly significant for research into sensory perception, neurobiology, and olfactory-related disorders. Studies with OR9Q2 can provide valuable insights into how the olfactory system works and influences behavior and physiology.

What types of OR9Q2 antibodies are commercially available and how do they differ?

Most commercially available OR9Q2 antibodies are polyclonal antibodies produced in rabbits, targeting the C-terminal region of human OR9Q2, typically amino acids 222-281 . These antibodies are primarily unconjugated and suitable for Western Blot (WB), ELISA, and Immunofluorescence (IF) applications. The primary differences between available antibodies include:

What is the molecular weight and cellular localization of OR9Q2 protein?

OR9Q2 has a calculated molecular weight of approximately 35 kDa (specifically 35,363 Da) . It is a membrane protein with multiple transmembrane domains (multi-pass membrane protein) localized to the plasma membrane . As a G-protein coupled receptor (GPCR), OR9Q2 features the characteristic seven-transmembrane domain structure common to this receptor family, with domains spanning the cell membrane for signal transduction functions. In experimental contexts, Western blot analysis typically shows detection of OR9Q2 at approximately 38 kDa in human cell lines such as HeLa and HT-29 .

What are the optimal conditions for using OR9Q2 antibodies in Western blot applications?

For optimal Western blot results with OR9Q2 antibodies, follow these methodological guidelines:

• Sample Preparation: Prepare lysates from human cells such as HeLa or HT-29, which have been documented to express detectable levels of OR9Q2 .

• Dilution Ratios: Use the antibody at a dilution range of 1:500-1:2000, with 1:1000 being a common starting point .

• Blocking Conditions: Use a buffer containing PBS with 0.5% BSA or 5% non-fat dry milk to reduce non-specific binding.

• Detection Method: For visualization, use an appropriate HRP-conjugated secondary antibody (typically anti-rabbit IgG) followed by enhanced chemiluminescence (ECL) detection.

• Validation Controls: Include a negative control by pre-incubating the antibody with the immunizing peptide to confirm specificity, as shown in Western blot analyses of HeLa and HT-29 cells .

• Expected Results: Anticipate detection of a band at approximately 38 kDa, which corresponds to the OR9Q2 protein .

How can I optimize immunofluorescence experiments using OR9Q2 antibodies?

For successful immunofluorescence experiments with OR9Q2 antibodies, implement the following protocol:

• Cell Preparation: Culture appropriate human cell lines that express OR9Q2. Adherent cell lines like HeLa or HT-29 can be grown on coverslips or specialized chamber slides.

• Fixation and Permeabilization: Fix cells with 4% paraformaldehyde for 15-20 minutes at room temperature, then permeabilize with 0.1-0.2% Triton X-100 for 5-10 minutes.

• Blocking: Block with 1-5% BSA in PBS for 30-60 minutes to reduce background signal.

• Primary Antibody Incubation: Apply OR9Q2 antibody at dilutions between 1:200-1:1000 (start with 1:500) and incubate overnight at 4°C .

• Secondary Antibody: Use fluorophore-conjugated anti-rabbit IgG (e.g., FITC or Alexa Fluor) at the manufacturer's recommended dilution (typically 1:1000) for 1 hour at room temperature.

• Counterstaining: Apply DAPI (1 μg/mL) for nuclear visualization.

• Mounting and Imaging: Mount with anti-fade medium and visualize using a confocal or fluorescence microscope, focusing on membrane localization patterns consistent with a GPCR distribution.

What protocols are recommended for ELISA applications with OR9Q2 antibodies?

For ELISA applications using OR9Q2 antibodies, follow this methodological approach:

• Coating: Coat the ELISA plate with the target antigen (OR9Q2 recombinant protein or synthesized peptide) at 1-10 μg/mL in carbonate buffer (pH 9.6) overnight at 4°C.

• Blocking: Block non-specific binding sites with 2-5% BSA in PBS for 1-2 hours at room temperature.

• Antibody Dilution: Apply the OR9Q2 antibody at a high dilution, typically 1:20000 for ELISA applications .

• Detection: Use an HRP-conjugated secondary antibody against rabbit IgG, followed by TMB substrate development and measurement at 450 nm using an ELISA plate reader .

• Data Analysis: End-point titers can be determined at the highest dilution with an S/N (Signal/Negative) ratio ≥2.1, using an irrelevant mAb as negative control .

• Controls: Include positive controls (known OR9Q2-expressing samples) and negative controls (buffer only and non-specific IgG) to validate results.

What are common issues encountered when using OR9Q2 antibodies and how can they be resolved?

Researchers commonly face several challenges when working with OR9Q2 antibodies:

• Non-specific Binding:

  • Problem: Multiple bands observed in Western blot.

  • Solution: Increase blocking concentration (5-10% BSA), optimize antibody dilution (try higher dilutions), and perform peptide competition assay to confirm specificity .

• Weak or No Signal:

  • Problem: Inability to detect OR9Q2 in samples.

  • Solution: Verify expression levels in your sample (OR9Q2 may have tissue-specific expression), reduce washing stringency, increase antibody concentration, and extend incubation time.

• High Background:

  • Problem: Excessive non-specific staining in immunofluorescence.

  • Solution: Increase blocking time/concentration, use more stringent washing protocols, and optimize antibody dilution.

• Inconsistent Results:

  • Problem: Variable results between experiments.

  • Solution: Standardize protocols, use consistent cell passage numbers, and ensure proper storage of antibodies (avoid repeated freeze-thaw cycles).

• Cross-Reactivity:

  • Problem: Antibody recognizing related olfactory receptors.

  • Solution: Use antibodies specifically validated against multiple olfactory receptors and confirm results with alternative detection methods or knockdown/knockout approaches.

How can I validate the specificity of OR9Q2 antibodies in my experimental system?

To validate OR9Q2 antibody specificity, implement these methodological approaches:

• Peptide Competition Assay: Pre-incubate the antibody with excess immunizing peptide before application to your experimental system. Specific signals should be significantly reduced or eliminated .

• Knockout/Knockdown Validation: Use CRISPR/Cas9 or siRNA approaches to reduce OR9Q2 expression in your cellular model. OR9Q2 sgRNA CRISPR/Cas9 systems are available for human OR9Q2 . Compare antibody signal between wild-type and knockout/knockdown samples.

• Multiple Antibody Validation: Use different antibodies targeting distinct epitopes of OR9Q2 to confirm consistent results.

• Cross-Species Validation: If working with animal models, test the antibody in tissues from multiple species where it claims reactivity (human, mouse, rat) .

• Positive and Negative Control Tissues: Include samples known to express OR9Q2 (e.g., olfactory epithelium) and those that don't express the protein.

• Western Blot Band Analysis: Confirm that the detected band appears at the expected molecular weight (~35-38 kDa) .

How can OR9Q2 antibodies be utilized in receptor-ligand binding studies?

For receptor-ligand binding studies involving OR9Q2, consider these methodological approaches:

• Surface Plasmon Resonance (SPR):

  • Immobilize OR9Q2 antibodies on a sensor chip to capture OR9Q2 protein.

  • Measure binding kinetics of potential ligands (e.g., 4-methylphenol) to the captured receptor.

  • Follow protocols similar to those used in antibody-antigen binding studies, where approximately 2500 RU of protein is immobilized on the flow cell, with BSA (5000 RU) as negative control .

  • Test concentrations ranging from 0-100 nM with association times of 210-300s and dissociation times of 600-900s .

• Co-Immunoprecipitation:

  • Use OR9Q2 antibodies to immunoprecipitate the receptor from cells exposed to potential ligands.

  • Analyze precipitated complexes to identify co-precipitating proteins involved in signaling pathways.

• Ligand-Dependent Activation Assays:

  • Treat cells expressing OR9Q2 with potential ligands (particularly 4-methylphenol).

  • Use OR9Q2 antibodies to track receptor internalization or conformational changes following ligand binding through immunofluorescence microscopy.

• Competitive Binding Assays:

  • Develop assays similar to the SARS-CoV-2 surrogate virus neutralization test, where OR9Q2 antibodies could be used to detect whether candidate ligands block the binding of known ligands to OR9Q2 .

What are the approaches for studying OR9Q2 expression patterns across different tissues and species?

To investigate OR9Q2 expression patterns across tissues and species, implement these methodological approaches:

• Comparative Immunohistochemistry:

  • Use OR9Q2 antibodies for immunohistochemical staining of tissue sections from different species (e.g., human, mouse, rat, cow).

  • Focus on olfactory epithelium and other tissues where expression has been documented.

  • Compare expression patterns to identify evolutionary conservation of OR9Q2 function, noting that OR9Q2 orthologs from chimpanzee, mouse, and cow have shown conserved 4-methylphenol detection functionality .

• Western Blot Analysis of Tissue Lysates:

  • Prepare protein lysates from various tissues across different species.

  • Perform Western blotting using OR9Q2 antibodies with appropriate positive controls.

  • Quantify relative expression levels across tissues and species.

• Single-Cell RNA-Seq Integration:

  • Correlate antibody-based protein detection with transcriptomic data.

  • Use OR9Q2 antibodies for sorting OR9Q2-expressing cells prior to RNA-Seq analysis.

• Evolutionary Studies:

  • Compare OR9Q2 function across species, with particular attention to bovine models, as the cow receptor has been reported to outperform human OR9Q2 10-fold in signal strength for 4-methylphenol detection .

How can I design experiments to investigate OR9Q2's role in olfactory signal transduction?

To investigate OR9Q2's role in olfactory signal transduction, consider these experimental approaches:

• Calcium Imaging in Heterologous Expression Systems:

  • Express OR9Q2 in HEK293 or other suitable cell lines.

  • Load cells with calcium-sensitive dyes.

  • Stimulate with 4-methylphenol and other potential ligands.

  • Use OR9Q2 antibodies for post-experiment immunofluorescence to correlate receptor expression with functional responses.

• G-Protein Coupling Analysis:

  • Use OR9Q2 antibodies in co-immunoprecipitation experiments to identify G-protein subunits that interact with OR9Q2.

  • Apply FRET/BRET approaches using tagged OR9Q2 and G-proteins to study interaction dynamics.

• Electrophysiological Recordings:

  • Perform patch-clamp recordings on OR9Q2-expressing cells.

  • Correlate electrophysiological responses to immunofluorescence staining patterns.

• In vivo Functional Imaging:

  • Develop transgenic models expressing reporters under OR9Q2 promoter control.

  • Use OR9Q2 antibodies to validate the fidelity of reporter expression.

  • Perform functional imaging during odor presentation, focusing on 4-methylphenol responses.

• CRISPR-Mediated Receptor Modification:

  • Use CRISPR/Cas9 systems to modify OR9Q2 sequences at key functional domains.

  • Assess the impact on ligand binding and signal transduction.

  • Validate mutant receptor expression using OR9Q2 antibodies before functional testing.

How does OR9Q2 expression differ between normal and pathological states?

Investigating OR9Q2 expression differences between normal and pathological states requires these methodological approaches:

• Comparative Tissue Analysis:

  • Collect paired normal and pathological tissue samples.

  • Perform immunohistochemistry using OR9Q2 antibodies with standardized protocols.

  • Quantify expression using digital image analysis to detect subtle differences.

• Western Blot Quantification:

  • Prepare protein lysates from normal and pathological tissues.

  • Conduct Western blot analysis using OR9Q2 antibodies with loading controls.

  • Use densitometry to quantify relative expression levels.

• Correlation with Clinical Parameters:

  • Design studies that integrate antibody-based detection of OR9Q2 with clinical data.

  • Analyze whether expression patterns correlate with disease progression or severity.

• Functional Assessment:

  • Compare ligand-binding properties and downstream signaling responses in normal versus pathological OR9Q2-expressing cells.

  • Use OR9Q2 antibodies to confirm receptor expression levels before functional testing.

• Genetic Variation Integration:

  • Cross-reference OR9Q2 protein expression patterns with known genetic variants.

  • Assess whether specific variants correlate with altered expression patterns detectable by OR9Q2 antibodies.

What approaches can be used to study the potential cross-reactivity of OR9Q2 antibodies with other olfactory receptors?

To assess potential cross-reactivity of OR9Q2 antibodies with other olfactory receptors, implement these methodological approaches:

• Epitope Analysis:

  • Perform in silico analysis of the immunogen sequence (e.g., amino acids 232-281) against other olfactory receptor proteins.

  • Identify receptors with high sequence similarity in the targeted epitope region.

• Recombinant Protein Panel Testing:

  • Express a panel of recombinant olfactory receptors, particularly those with sequence similarity to OR9Q2.

  • Perform Western blot or ELISA to test antibody binding to each receptor.

• Knockout/Knockdown Validation:

  • Generate cellular models with CRISPR/Cas9-mediated knockout of OR9Q2 .

  • Test whether antibody signal is completely eliminated (suggesting specificity) or partially retained (suggesting cross-reactivity).

• Competitive Binding Assays:

  • Perform peptide competition assays using peptides from OR9Q2 and related olfactory receptors.

  • Compare the ability of different peptides to block antibody binding.

• Immunoprecipitation-Mass Spectrometry:

  • Use OR9Q2 antibodies for immunoprecipitation from tissue extracts.

  • Analyze precipitated proteins by mass spectrometry to identify potential cross-reactive targets.

How can OR9Q2 antibodies be integrated into high-throughput screening protocols for odorant discovery?

For integrating OR9Q2 antibodies into high-throughput screening protocols for odorant discovery, consider these methodological approaches:

• Automated Immunofluorescence Platforms:

  • Establish cell lines stably expressing OR9Q2.

  • Develop high-content imaging protocols using OR9Q2 antibodies to detect receptor internalization or clustering following ligand binding.

  • Screen compound libraries for molecules that induce receptor conformational changes or trafficking.

• ELISA-Based Screening:

  • Develop competitive ELISA formats where potential ligands compete with known OR9Q2 binders.

  • Use OR9Q2 antibodies to detect conformational changes in the receptor upon ligand binding.

  • Apply high-throughput ELISA protocols similar to those used in neutralizing antibody assays .

• Biosensor Development:

  • Immobilize OR9Q2 antibodies on biosensor platforms.

  • Monitor ligand-induced changes in receptor conformation or downstream signaling.

  • Adapt protocols from high-throughput neutralizing antibody assays that detect protein-protein interactions .

• Flow Cytometry Screening:

  • Develop fluorescence-based assays where OR9Q2 antibodies are used to quantify receptor surface expression after exposure to potential ligands.

  • Sort cells based on antibody binding patterns following odorant exposure.

• Integration with Functional Readouts:

  • Combine antibody-based detection of OR9Q2 with calcium imaging or other functional assays.

  • Correlate receptor expression levels (detected via antibodies) with functional responses to develop structure-activity relationships.

What emerging technologies might enhance the application of OR9Q2 antibodies in sensory neuroscience?

Emerging technologies that could enhance OR9Q2 antibody applications in sensory neuroscience include:

• Single-Molecule Localization Microscopy:

  • Apply super-resolution techniques (STORM, PALM) using OR9Q2 antibodies to visualize nanoscale organization of receptors in the olfactory cilia.

  • Track receptor clustering and organization in response to odorant exposure.

• Spatial Transcriptomics Integration:

  • Combine OR9Q2 antibody-based immunohistochemistry with spatial transcriptomics.

  • Correlate protein expression patterns with transcriptomic profiles in specific olfactory epithelium regions.

• Antibody-Based Optogenetics:

  • Develop approaches where OR9Q2 antibodies are conjugated to photosensitive moieties.

  • Enable light-controlled manipulation of receptor function or visualization.

• Cryo-EM Structure Determination:

  • Use OR9Q2 antibodies to stabilize receptor conformations for structural studies.

  • Apply single-particle cryo-EM to determine detailed receptor structure in various activation states.

• Organoid Technologies:

  • Develop olfactory epithelium organoids.

  • Apply OR9Q2 antibodies to track receptor expression during organoid development and in response to odorant exposure.

How can computational approaches be combined with OR9Q2 antibody data to better understand olfactory coding?

Integration of computational approaches with OR9Q2 antibody data can enhance understanding of olfactory coding through:

• Structural Modeling and Docking:

  • Use antibody epitope mapping data to refine structural models of OR9Q2.

  • Perform virtual screening of chemical libraries against these refined models.

  • Validate computational predictions using antibody-based binding and functional assays.

• Machine Learning Integration:

  • Train machine learning algorithms on datasets that include antibody-detected OR9Q2 expression patterns.

  • Develop predictive models for receptor-ligand interactions based on structural and expression data.

  • Use these models to predict novel ligands for OR9Q2, particularly those similar to 4-methylphenol .

• Network Analysis:

  • Combine antibody-detected protein-protein interactions with transcriptomic data.

  • Build comprehensive signaling networks for OR9Q2-mediated olfactory transduction.

  • Identify key nodes that could serve as therapeutic targets for olfactory disorders.

• Systems Biology Approaches:

  • Integrate antibody-based detection of OR9Q2 with metabolomic and proteomic datasets.

  • Develop comprehensive models of olfactory signal processing that incorporate receptor expression dynamics.

• Digital Pathology and AI:

  • Apply artificial intelligence to analyze immunohistochemical staining patterns of OR9Q2 across large tissue datasets.

  • Identify subtle patterns in receptor expression that correlate with physiological or pathological states.